Compare Heron Therapeutics Inc (HRTX) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Vanguard Total World Stock Index Fund ETF — how do they compare? Heron Therapeutics Inc trades at $0.39 (market cap $68.01M), while Vanguard Total World Stock Index Fund ETF trades at $159.34 (market cap $101.70B). The key difference: Vanguard Total World Stock Index Fund ETF is far larger — about 1495.4× Heron Therapeutics Inc's market cap, and Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Vanguard Total World Stock Index Fund ETF for 53 Days on average.
| HRTX | VT | |
|---|---|---|
Market Cap | $68.01M | $101.70B |
Volume | 1,891,941 | 1,783,794 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.49 | $162.39 |
52-Week Low | $0.27 | $134.19 |
Typical Hold Time | 35 Days | 53 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
VT, the Vanguard Total World Stock ETF, trades at $159.39, down 0.16% on the day. Technical indicators show a bearish bias with moving averages signaling selling pressure, while oscillators remain neutral. The ETF offers broad global diversification with over 9,700 stocks and a low expense ratio of 0.06%, though key valuation ratios like P/E and P/B are not disclosed in the provided data. Recent news highlights its role as a core holding for long-term investors seeking worldwide exposure.
The outlook for VT is supported by its cost efficiency and diversification benefits, but near-term technical weakness and competitive pressures from lower-fee alternatives pose risks. Investor sentiment is mixed, with some analysts favoring VT for its comprehensive coverage, while others point to higher expenses relative to peers. Macroeconomic uncertainties and trade tensions could impact global equity returns, affecting VT's performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
